Diploma (DPLM) Competitors

Dechra Pharmaceuticals (LON:DPH) and Diploma (LON:DPLM) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, community ranking, earnings, risk, institutional ownership, dividends and valuation.

Which has more volatility & risk, DPH or DPLM?

Dechra Pharmaceuticals has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Diploma has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.

Is DPH or DPLM more profitable?

Diploma has a net margin of 9.25% compared to Dechra Pharmaceuticals' net margin of -3.66%. Diploma's return on equity of 13.39% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%
Diploma	9.25%	13.39%	8.32%

Do insiders and institutionals believe in DPH or DPLM?

105.5% of Dechra Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Diploma shares are owned by institutional investors. 9.3% of Dechra Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Diploma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer DPH or DPLM?

Dechra Pharmaceuticals received 62 more outperform votes than Diploma when rated by MarketBeat users. Likewise, 63.00% of users gave Dechra Pharmaceuticals an outperform vote while only 61.84% of users gave Diploma an outperform vote.

Company	Underperform	Outperform
Dechra Pharmaceuticals	Outperform Votes 344 63.00%	Underperform Votes 202 37.00%
Diploma	Outperform Votes 282 61.84%	Underperform Votes 174 38.16%

Is DPH or DPLM a better dividend stock?

Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. Diploma pays an annual dividend of GBX 57 per share and has a dividend yield of 1.3%. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend. Diploma pays out 6,627.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Which has better earnings and valuation, DPH or DPLM?

Diploma has higher revenue and earnings than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than Diploma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A
Diploma	£1.26B	4.57	£116.10M	£0.86	4,990.70

Does the media prefer DPH or DPLM?

In the previous week, Diploma had 5 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 5 mentions for Diploma and 0 mentions for Dechra Pharmaceuticals. Diploma's average media sentiment score of 1.24 beat Dechra Pharmaceuticals' score of 0.00 indicating that Diploma is being referred to more favorably in the news media.

Company	Overall Sentiment
Dechra Pharmaceuticals	Neutral
Diploma	Positive

Do analysts prefer DPH or DPLM?

Diploma has a consensus price target of GBX 4,555, indicating a potential upside of 6.13%. Given Diploma's stronger consensus rating and higher possible upside, analysts clearly believe Diploma is more favorable than Dechra Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dechra Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diploma	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Diploma beats Dechra Pharmaceuticals on 13 of the 19 factors compared between the two stocks.